|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||93.05 / 127.00|
A selloff in crude oil proves another roadblock in the Dow Jones Industrial Average's pursuit of 20,000.
Here's what the market chose to focus on instead.
Celgene executives have raised guidance for the year, but the stock retreated Monday.
Celgene Corporation (NASDAQ:CELG) today provided a business update as well as its preliminary 2016 unaudited results and financial guidance for 2017 at the 35 th Annual J.
It doesn't really matter where you think a stock should trade at.
Doug Kass shares his thoughts on the deepening of retail stocks' weakness and the Amazon Effect.
Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.
Jim Cramer breaks down why it is so difficult to buy drug stocks right now.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
I bought ProShares Ultra QQQ ETF and Tarena International and sold two-thirds of my Ross Stores.
Celgene Corporation (NASDAQ:CELG) will host a conference call and live audio webcast on Thursday, January 26, 2017 at 9 a.
During the 35 th Annual J.P.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Doug Kass shares his thoughts on how 2017 will be the year of 'the Dude.'
Kass' trade of the year for 2017 is to short the PowerShares QQQ Trust ETF.
Doug Kass shares his thoughts on the post-fact investment world and delivers his verdict on Caterpillar.
Jim Cramer favors UnitedHealth over Cerner, and U.S. Concrete more than Cemex.
Get used to some down days, says Jim Cramer, but don't lose sight of the success for financial stocks.
TheStreet's biotech columnist offers his own report card on biotech stocks.
Celgene announced today that the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending the use of OTEZLA (apremilast) for the treatment of adult patients with...
Juno Therapeutics, Inc. (NASDAQ: JUNO) and Celgene Corporation (NASDAQ: CELG), today announced that the U.
Celgene Corporation (NASDAQ:CELG) today announced that OTEZLA ® (apremilast), Celgene's oral selective inhibitor of phosphodiesterase 4 (PDE4), has been granted full marketing authorization by Japan's Ministry of...
Doug Kass shares his thoughts on divergences in the market's armor and observes that real tech regulation is complicated.
Cramer shares his views on Diamondback's Permian buy and wonders if airlines will soon be playing leapfrog.
Doug Kass shares his thoughts on China and life insurers.
Agios owns the full rights to both drugs in the PKD development program, which makes them particularly important to the company.